The global Parkinson’s disease therapeutics market size is expected to reach around US$ 5.24 Bn by 2026 and is projected to witness cumulative annual growth rate (CAGR) of more than 12.7% from 2019 to 2026. The global Parkinson’s disease therapeutics market is witnessing a relatively high growth owing to rise in awareness regarding Parkinson’s disease, rapidly growing geriatric population, promising pipeline drugs, and new product launches. The global Parkinson’s disease therapeutics market is growing with high prevalence and rise in incidences of Parkinson’s disease across the developed countries.
The report analyzes and forecasts the parkinson’s disease therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of parkinson’s disease therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major parkinson’s disease therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of parkinson’s disease therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of parkinson’s disease therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global parkinson’s disease therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the parkinson’s disease therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of parkinson’s disease therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Major players operating in the global Parkinson’s disease therapeutics market are AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc, which exhibit the widest geographical outreach. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.
The global Parkinson’s disease therapeutics market is segmented as follows:
By Drug Class
By Route of Administration
By Distribution Channel
By Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary: Global Parkinson’s Disease Therapeutics Market
Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments
Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2017–2026
5.5. Global Parkinson’s Disease Therapeutics Market Outlook
5.6. Global Prevalence of Parkinson’s Disease
5.7. Pipeline Analysis
Chapter 6 Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
6.3.1. Levodopa Combination
6.3.2. Dopamine Agonists
6.3.3. MAO-B Inhibitors
6.3.4. COMT Inhibitors
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
Chapter 7 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2026
7.2.1. Oral
7.2.2. Transdermal
7.2.3. Subcutaneous
7.2.4. Intestinal Infusion
7.2.5. Others
7.3. Market Attractiveness Analysis, by Route of Administration
7.4. Key Trends
Chapter 8 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2026
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
Chapter 9 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2026
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region
Chapter 10 North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017-2026
10.2.1. U.S.
10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
10.3.1. Levodopa Combination
10.3.2. Dopamine Agonists
10.3.3. MAO-B Inhibitors
10.3.4. COMT Inhibitors
10.3.5. Others
10.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2026
10.4.1. Oral
10.4.2. Transdermal
10.4.3. Subcutaneous
10.4.4. Intestinal Infusion
10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2026
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Route of Administration
10.6.4. By Distribution Channel
Chapter 11 Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2026
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
11.3.1. Levodopa Combination
11.3.2. Dopamine Agonists
11.3.3. MAO-B Inhibitors
11.3.4. COMT Inhibitors
11.3.5. Others
11.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2026
11.4.1. Oral
11.4.2. Transdermal
11.4.3. Subcutaneous
11.4.4. Intestinal Infusion
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2026
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
11.6.1. By Country
11.6.2. By Drug Class
11.6.3. By Route of Administration
11.6.4. By Distribution Channel
Chapter 12 Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2026
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
12.4.1. Levodopa Combination
12.4.2. Dopamine Agonists
12.4.3. MAO-B Inhibitors
12.4.4. COMT Inhibitors
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2026
12.5.1. Oral
12.5.2. Transdermal
12.5.3. Subcutaneous
12.5.4. Intestinal Infusion
12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2026
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country
12.7.2. By Drug Class
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
Chapter 13 Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2026
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
13.4.1. Levodopa Combination
13.4.2. Dopamine Agonists
13.4.3. MAO-B Inhibitors
13.4.4. COMT Inhibitors
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2026
13.5.1. Oral
13.5.2. Transdermal
13.5.3. Subcutaneous
13.5.4. Intestinal Infusion
13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2026
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
Chapter 14 Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2026
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
14.4.1. Levodopa Combination
14.4.2. Dopamine Agonists
14.4.3. MAO-B Inhibitors
14.4.4. COMT Inhibitors
14.4.5. Others
14.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2026
14.5.1. Oral
14.5.2. Transdermal
14.5.3. Subcutaneous
14.5.4. Intestinal Infusion
14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2026
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
Chapter 15 Competition Landscape
15.1. Global Parkinson’s Disease Therapeutics Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. AbbVie, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.2. UCB Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.3. Merck & Co., Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.4. Valeant Pharmaceuticals International, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.5. Novartis AG
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.6. Boehringer Ingelheim GmbH.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.7. GlaxoSmithKline plc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.8. Teva Pharmaceutical Industries Ltd.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.9. STADA Arzneimittel AG.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.10. Impax Laboratories, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.11. F. Hoffmann-La Roche Ltd.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers